5 completed, 3 terminated. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Terminated 3 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow lorcaserin: new trials by email Literature Review of lorcaserin trials Research Report on lorcaserin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome Placebo, Lorcaserin - Epilepsies, Myoclonic | Phase 3 | Terminated | Eisai Inc. | 22 | 2020-09-23 | 2025-10-08 |
| Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients Lorcaserin 10 mg BID, Matching Placebo BID - Obesity | Phase 3 | Terminated | Kanion & Huawe Medicine Co.,Ltd | 100 | 2019-09-17 | 2022-05-02 |
| Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder Lorcaserin, Placebo - Opioid-use Disorder | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 60 | 2017-05-25 | 2020-10-05 |
| Addressing Post Cessation Weight Gain lorcaserin, Varenicline, Placebo - Obesity, Smoking Cessation | Phase 2 / Phase 3 | Terminated | Mayo Clinic | 84 | 2016-06-15 | 2021-06-10 |
| Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management LLLT, Lorcaserin - Overweight, Obese | Phase 3 | Completed | Mayo Clinic | 44 | 2014-06-01 | 2016-11-22 |
| BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo - Obesity | Phase 3 | Completed | Eisai Inc. | 4008 | 2008-01-01 | 2019-10-04 |
| BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo - Obesity | Phase 3 | Completed | Eisai Inc. | 604 | 2007-12-01 | 2019-10-02 |
| BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management Lorcaserin 10 mg BID, Matching Placebo BID - Obesity | Phase 3 | Completed | Eisai Inc. | 3182 | 2006-11-01 | 2019-10-02 |
Obesity (6) · Cardiovascular Diseases (3) · Dyslipidemias (3) · Hypertension (3) · Sleep Apnea Syndromes (3) · Weight Loss (3) · Overweight (2) · Epilepsies, Myoclonic (1) · Epilepsy (1) · Obesity, Abdominal (1) · Opioid-Related Disorders (1) · Seizures (1) · Smoking Cessation (1)
Eisai Inc. (4) · Mayo Clinic (2) · Kanion & Huawe Medicine Co.,Ltd (1) · New York State Psychiatric Institute (1)
United States (7) · Canada (1) · China (1)
Frances R Levin, MD (1) · Ivana T. Croghan, PhD (1) · Ryan T Hurt, MD, PhD (1) · Xiaohui Guo, Ph. D (1)
PMID 23661689, PMID 27206567, PMID 27659698, PMID 27888609, PMID 27116910, PMID 20647200, PMID 21795446, PMID 22421927, PMID 27389084, PMID 27708788, PMID 28345809, PMID 36160639
K23DA037299 (1)